Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

Differential expression analysis for sequence count data

Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581

Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments

Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,363

Cancer drug resistance: an evolving paradigm

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

STATs in cancer inflammation and immunity: a leading role for STAT3

Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169

Epidermal growth factor receptor mutations in lung cancer

Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170

Stat3 as an Oncogene

Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051

Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation

Wen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974

Fast and SNP-tolerant detection of complex variants and splicing in short reads

Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

O’Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,270

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

Roesch, A., Fukunaga‐Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., Basu, D., Gimotty, P. A., VOGT, T. M., & Herlyn, M. (2010) · Cell · doi:10.1016/j.cell.2010.04.020 · Cited by 1,177

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967

Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy

Huang, Q., Li, F., Liu, X., Li, W., Shi, W., Liu, F.-F., O'Sullivan, B., He, Z., Peng, Y., Tan, A.-C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2385 · Cited by 886

Stat proteins and oncogenesis

Bromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15617 · Cited by 863

Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions

Shuai, K., Horvath, C. M., Huang, L. H. T., Qureshi, S. A., Cowburn, D., & Darnell, J. E. (1994) · Cell · doi:10.1016/0092-8674(94)90357-3 · Cited by 807

Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia

Rajala, H. L. M., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmäki, H. A., Andersson, E. I., Lagström, S., Clemente, M. J., Olson, T. L., Jalkanen, S. E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114885 · Cited by 791

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732

Tumor adaptation and resistance to RAF inhibitors

Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4055 · Cited by 504

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Wang, S. E., Narasanna, A., Pérez-Torres, M., Xiang, B., Wu, F. Y., Yang, S., Carpenter, G. F., Gazdar, A. F., Muthuswamy, S. K., & Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.023 · Cited by 479

Oncogene addiction: setting the stage for molecularly targeted cancer therapyPreprint

Sharma, S. V., & Settleman, J. E. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 451

Strategies to overcome resistance to targeted protein kinase inhibitors

Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 337

Nonreceptor Tyrosine Kinase BMX Maintains Self-Renewal and Tumorigenic Potential of Glioblastoma Stem Cells by Activating STAT3

Guryanova, O. A., Wu, Q., Cheng, L., Lathia, J. D., Huang, Z., Yang, J. B., MacSwords, J., Eyler, C. E., McLendon, R. E., Heddleston, J. M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.004 · Cited by 262

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas

Pilati, C., Amessou, M., Bihl, M., Balabaud, C. P., Nhieu, J. T. V., Paradis, V., Nault, J., Izard, T., Bioulac‐Sage, P., Couchy, G., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110283 · Cited by 252

The Evolving War on Cancer

Haber, D. A., Gray, N. S., & Baselga, J. M. (2011) · Cell · doi:10.1016/j.cell.2011.03.026 · Cited by 219

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers

Wang, X., Crowe, P. J., Goldstein, D., & Yang, J. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1568 · Cited by 204

Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation

Kim, S. M., Kwon, O.-J., Hong, Y. K., Kim, J. H., Solca, F., Ha, S., Soo, R. A., Christensen, J. G., Lee, J. H., & Cho, B. C. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0311 · Cited by 202

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

Yonesaka, K., Zejnullahu, K., Lindeman, N. I., Homes, A. J., Jackman, D. M., Zhao, F., Rogers, A. M., Johnson, B. E., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0957 · Cited by 121

MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines

Vultur, A., Villanueva, J., Krepler, C., Rajan, G., Chen, Q., Xiao, M., Li, L., Gimotty, P. A., Wilson, M. A., Hayden, J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.131 · Cited by 101

Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M

Lee, H.-J., Schaefer, G., Heffron, T. P., Shao, L., Ye, X., Sideris, S., Malek, S., Chan, E., Merchant, M., La, H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0357 · Cited by 90

Oncogenic PI3K Mutations Lead to NF-κB–Dependent Cytokine Expression following Growth Factor Deprivation

Hutti, J. E., Pfefferle, A. D., Russell, S. C., Sircar, M., Perou, C. M., & Baldwin, A. S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4141 · Cited by 84

From regulation of dying cell engulfment to development of anti-cancer therapy

Krysko, D. V., & Vandenabeele, P. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402271 · Cited by 71

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110

Emerging Biological Principles of Metastasis

Lambert, A. W., Pattabiraman, D. R., & Weinberg, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.11.037 · Cited by 3,191

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985

Understanding and targeting resistance mechanisms in NSCLC

Rotow, J. K., & Bivona, T. G. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.84 · Cited by 997

JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression

Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 728

Abstract 4425: Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells

Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H., & Settleman, J. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-4425

Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism

Zhao, C., Li, H., Lin, H.-J. L., Yang, S., Lin, J., & Liang, G. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.001 · Cited by 237

Feedback Activation of STAT3 Is a Widespread Drug-Resistance Mechanism

(2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2014-165 · Cited by 2

Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer

Wang, X., Jiang, W., Du, Y., Dongqi, Z., Zhang, J., Fang, C., Fang, Y., & Chen, Z.-S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100884 · Cited by 53

The STAT3 oncogene as a predictive marker of drug resistance

Barré, B., Vigneron, A. M., Perkins, N. D., Roninson, I. B., Gamelin, E. C., & Coqueret, O. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.001 · Cited by 123